Enhancing cancer vaccine efficacy via modulation of the tumor microenvironment

Clinical Cancer Research

Volumn 15, Issue 21, 2009, Pages 6476-6478

  Disis, Mary L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; INTERLEUKIN 12; PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUMOR ANTIGEN; VACCINE;

CYTOTOXIC T LYMPHOCYTE; GLIOMA; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INFLAMMATION; MICROENVIRONMENT; MODULATION; NEOPLASM; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE; TH17 CELL; TUMOR; TUMOR ESCAPE; TUMOR MODEL; UNITED STATES; WART VIRUS;

ANIMALS; AUTOANTIGENS; CANCER VACCINES; FEMALE; IMMUNE TOLERANCE; IMMUNOMODULATION; MALE; MICE; MODELS, IMMUNOLOGICAL; NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TUMOR ESCAPE;

EID: 70350721788     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2256     Document Type: Short Survey

References (15)

1. Ueda R, Fujita M, Zhu X, et al. Systemic inhibition of transforming growth factor-β in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res 2009;15:6551-6559
2. + T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-β monoclonal antibody. Clin Cancer Res 2009;15:6560-6569
3. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296-306. (Pubitemid 40516155)
4. Gajewski TF. Failure at the effector phase: immune barriers at the level of themelanoma tumor micro-environment. Clin Cancer Res 2007;13:5256-5261
5. Li MO, Flavell RA. TGF-β: a master of all T cell trades. Cell 2008;134:392-404.
6. Kapp JA, Honjo K, Kapp LM, Goldsmith K, Bucy RP. Antigen, in the presence of TGF-β, induces up-regulation of FoxP3gfp+ in CD4+ TCR transgenic T cells that mediate linked suppression of CD8+ T cell responses. J Immunol 2007;179: 2105-2114
7. Liu XS, Leerberg J, MacDonald K, Leggatt GR, Frazer IH. IFN-γ promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host. J Immunol 2009;183:51-58
8. Sanjabi S, Mosaheb MM, Flavell RA. Opposing effects of TGF-β and IL-15 cytokines control the number of short-lived effector CD8+ T cells. Immunity 2009;31:131-144
9. Markiewicz MA, Wise EL, Buchwald ZS, et al. IL-12 enhances CTL synapse formation and induces self-reactivity. J Immunol 2009;182: 1351-1361
10. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009; 27:485-517.
11. Muranski P, Boni A, Antony PA, et al. Tumor- specific Th17-polarized cells eradicate large established melanoma. Blood 2008;112: 362-373
12. Hinrichs CS, Kaiser A, Paulos CM, et al. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 2009;114:596-599
13. Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009;114:1141-1149
14. Santarlasci V, Maggi L, Capone M, et al. TGF-β indirectly favors the development of human Th17 cells by inhibiting Th1 cells. Eur J Immunol 2009;39:207-215
15. Padua D, Massague J. Roles of TGFβ in metastasis. Cell Res 2009;19:89-102.